Myelofibrosis (MF) is the most aggressive Philadelphia-chromosome negative myeloproliferative neoplasm (MPN), typified by abnormal proliferation and differentiation of hematopoietic progenitors, variable degree of bone marrow fibrosis and cytopenias, elevated circulating CD34+ cells, splenomegaly and risk of blast transformation (BT) [1,2]. This evidence concerns the gene CD34 and myeloproliferative disorder.